min. read
A group of drugs called immune checkpoint inhibitors can augment the anti-cancer effect of genetically engineered T cells. With support from The Faris Foundation, Texas Children’s Cancer Center is beginning the HEROS 3.0 trial, our most advanced clinical trial to date recurrent sarcomas, a type of cancer of the muscle or bone.
Related Stories
Press Release
Nov 26, 2024
Texas Children’s Celebrates 40th Anniversary of Pioneering Heart Transplant Program
Press Release
Nov 19, 2024
26th Annual Bad Pants Open Golf Tournament Raises Over $400,000 for Texas Children’s Neonatal I...
Press Release
Oct 24, 2024
Longtime Texas Children’s Pediatricians and Physician Leaders Dr. Sapna Singh and Dr. Terry Yen...
21521
Press Release
video